Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial
Zhao, Hong, Zhang, Chi, Zhu, Qi, Chen, Xianxiang, Chen, Guilin, Sun, Wenjin, Xiao, Zuohan, Du, Weijun, Yao, Jing, Li, Guojun, Ji, Yanhua, Li, Niuniu, Jiang, Yujin, Wang, Ying, Zeng, Qingjin, Li, Wei, Gong, Beilei, Chang, Xianyou, Zhu, Feng, Jiang, Xiufeng, Li, Jiawen, Wu, Zhao, Liu, Yingxia, Peng, Peng, Wang, Guiqiang
Published in International immunopharmacology (01.08.2021)
Published in International immunopharmacology (01.08.2021)
Get full text
Journal Article
Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial
Zhao, Hong, Zhang, Chi, Zhu, Qi, Chen, Xianxiang, Chen, Guilin, Sun, Wenjin, Xiao, Zuohan, Du, Weijun, Yao, Jing, Li, Guojun, Ji, Yanhua, Li, Niuniu, Jiang, Yujin, Wang, Ying, Zeng, Qingjin, Li, Wei, Gong, Beilei, Chang, Xianyou, Zhu, Feng, Jiang, Xiufeng, Li, Jiawen, Wu, Zhao, Liu, Yingxia, Peng, Peng, Wang, Guiqiang
Published in International immunopharmacology (01.08.2021)
Get full text
Published in International immunopharmacology (01.08.2021)
Journal Article